Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng, Jiangsu 224000, P.R. China.
Department of Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Mol Med Rep. 2020 Mar;21(3):1365-1373. doi: 10.3892/mmr.2020.10923. Epub 2020 Jan 9.
The present prospective study was conducted to investigate the independent risk and predictive value of plasma long non‑coding RNA metastasis‑associated lung adenocarcinoma transcript 1 (MALAT1) as a biomarker for the diagnosis, severity and prognosis of sepsis. A total of 120 patients with sepsis and 60 healthy controls (HCs) were recruited. The expression levels of plasma MALAT1 were detected by quantitative PCR. The results demonstrated that the plasma levels of MALAT1 were significantly increased in patients with sepsis compared with HCs (P<0.001), in patients with septic shock compared with in patients without septic shock (P<0.001), and in non‑survivors compared with in survivors (P<0.001). MALAT1 plasma levels exhibited weak positive correlation with serum procalcitonin levels (r=0.253; P=0.005), arterial lactate levels (r=0.488; P<0.001), sepsis‑related organ failure assessment scores (r=0.566; P<0.001), and acute physiology and chronic health evaluation II scores (r=0.517; P<0.001) in patients with sepsis. Multivariate logistic regression analysis revealed that high MALAT1 expression was an independent risk factor for sepsis (P<0.001), septic shock (P=0.030) and poor prognosis (P=0.015). In addition, the receiver operating characteristic curve exhibited a significant predictive value for MALAT1 in distinguishing patients with sepsis from HCs with an area under the curve (AUC) of 0.910, patients with septic shock from patients without shock with an AUC of 0.836, and non‑survivors from survivors with an AUC of 0.886. In conclusion, plasma MALAT1 may serve as a biomarker for the diagnosis, severity and prognosis of sepsis.
本前瞻性研究旨在探讨血浆长链非编码 RNA 转移相关肺腺癌转录本 1（MALAT1）作为生物标志物用于诊断、严重程度和预测脓毒症的独立风险和预测价值。共纳入 120 例脓毒症患者和 60 例健康对照者（HCs）。采用实时定量 PCR 检测血浆 MALAT1 的表达水平。结果显示，与 HCs 相比，脓毒症患者的血浆 MALAT1 水平显著升高（P<0.001），与无休克脓毒症患者相比，休克脓毒症患者的 MALAT1 水平显著升高（P<0.001），与存活者相比，死亡者的 MALAT1 水平显著升高（P<0.001）。MALAT1 血浆水平与血清降钙素原水平（r=0.253；P=0.005）、动脉血乳酸水平（r=0.488；P<0.001）、脓毒症相关器官衰竭评估评分（r=0.566；P<0.001）和急性生理学和慢性健康评估 II 评分（r=0.517；P<0.001）呈弱正相关。多因素 logistic 回归分析显示，高 MALAT1 表达是脓毒症（P<0.001）、脓毒性休克（P=0.030）和预后不良（P=0.015）的独立危险因素。此外，受试者工作特征曲线显示 MALAT1 对鉴别脓毒症患者与 HCs 的预测价值显著，曲线下面积（AUC）为 0.910，鉴别休克脓毒症患者与非休克患者的 AUC 为 0.836，鉴别死亡患者与存活患者的 AUC 为 0.886。综上所述，血浆 MALAT1 可能是诊断、严重程度和预测脓毒症的生物标志物。
